| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Osteogenesis Imperfecta | 26 | 2024 | 147 | 4.220 |
Why?
|
| Metabolism, Inborn Errors | 10 | 2022 | 104 | 3.010 |
Why?
|
| Phenotype | 54 | 2023 | 4207 | 2.020 |
Why?
|
| Genetic Testing | 14 | 2020 | 990 | 1.920 |
Why?
|
| Abnormalities, Multiple | 15 | 2021 | 974 | 1.740 |
Why?
|
| Craniofacial Abnormalities | 12 | 2022 | 243 | 1.710 |
Why?
|
| Dwarfism | 10 | 2022 | 102 | 1.570 |
Why?
|
| Intellectual Disability | 16 | 2022 | 1042 | 1.550 |
Why?
|
| Urogenital Abnormalities | 10 | 2023 | 167 | 1.450 |
Why?
|
| Limb Deformities, Congenital | 9 | 2022 | 104 | 1.420 |
Why?
|
| Genetics, Medical | 5 | 2020 | 117 | 1.270 |
Why?
|
| Neonatal Screening | 5 | 2017 | 187 | 1.260 |
Why?
|
| Chromosomes, Human, Pair 14 | 10 | 2019 | 99 | 1.150 |
Why?
|
| Mutation | 37 | 2023 | 5749 | 1.140 |
Why?
|
| Genetic Diseases, Inborn | 11 | 2019 | 440 | 1.070 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 6 | 2019 | 101 | 1.030 |
Why?
|
| Humans | 185 | 2024 | 121743 | 0.970 |
Why?
|
| Exome | 19 | 2022 | 1037 | 0.950 |
Why?
|
| Genetic Variation | 9 | 2020 | 1475 | 0.940 |
Why?
|
| Prenatal Diagnosis | 10 | 2023 | 580 | 0.940 |
Why?
|
| Urea Cycle Disorders, Inborn | 3 | 2021 | 78 | 0.920 |
Why?
|
| Collagen Type I | 6 | 2023 | 110 | 0.860 |
Why?
|
| Transposases | 3 | 2022 | 40 | 0.860 |
Why?
|
| Propionic Acidemia | 5 | 2019 | 10 | 0.860 |
Why?
|
| Disorders of Sex Development | 5 | 2019 | 80 | 0.840 |
Why?
|
| Child, Preschool | 59 | 2021 | 13771 | 0.830 |
Why?
|
| Hyperammonemia | 3 | 2021 | 60 | 0.820 |
Why?
|
| Autism Spectrum Disorder | 4 | 2022 | 373 | 0.820 |
Why?
|
| Bone Density | 6 | 2024 | 307 | 0.810 |
Why?
|
| Language Development Disorders | 3 | 2019 | 173 | 0.800 |
Why?
|
| Focal Dermal Hypoplasia | 4 | 2016 | 18 | 0.790 |
Why?
|
| Female | 116 | 2024 | 64492 | 0.790 |
Why?
|
| Genomic Imprinting | 6 | 2019 | 123 | 0.790 |
Why?
|
| Genetic Association Studies | 8 | 2020 | 756 | 0.770 |
Why?
|
| Bone and Bones | 7 | 2022 | 262 | 0.750 |
Why?
|
| Metabolomics | 9 | 2021 | 389 | 0.750 |
Why?
|
| Male | 110 | 2024 | 59138 | 0.750 |
Why?
|
| Child | 76 | 2023 | 24035 | 0.740 |
Why?
|
| Aicardi Syndrome | 2 | 2018 | 14 | 0.740 |
Why?
|
| Adrenal Hyperplasia, Congenital | 2 | 2018 | 34 | 0.740 |
Why?
|
| Developmental Disabilities | 11 | 2022 | 692 | 0.720 |
Why?
|
| Sequence Analysis, DNA | 11 | 2019 | 1758 | 0.710 |
Why?
|
| Adolescent | 56 | 2023 | 18879 | 0.690 |
Why?
|
| Genetic Markers | 3 | 2018 | 597 | 0.690 |
Why?
|
| Genetic Predisposition to Disease | 13 | 2021 | 3066 | 0.680 |
Why?
|
| Scoliosis | 5 | 2020 | 134 | 0.670 |
Why?
|
| Autistic Disorder | 2 | 2019 | 343 | 0.660 |
Why?
|
| Rare Diseases | 4 | 2020 | 185 | 0.650 |
Why?
|
| Infant | 46 | 2022 | 12289 | 0.650 |
Why?
|
| Adult | 58 | 2024 | 28623 | 0.640 |
Why?
|
| Fractures, Bone | 4 | 2023 | 179 | 0.610 |
Why?
|
| Genomics | 7 | 2020 | 1473 | 0.610 |
Why?
|
| Lysosomal Storage Diseases | 2 | 2018 | 36 | 0.590 |
Why?
|
| Citrullinemia | 2 | 2014 | 15 | 0.580 |
Why?
|
| Young Adult | 29 | 2024 | 8712 | 0.570 |
Why?
|
| Laboratories | 2 | 2020 | 83 | 0.570 |
Why?
|
| Genetic Counseling | 4 | 2017 | 221 | 0.560 |
Why?
|
| Infant, Newborn | 32 | 2023 | 8088 | 0.560 |
Why?
|
| Dexamethasone | 1 | 2018 | 274 | 0.560 |
Why?
|
| Microcephaly | 4 | 2022 | 324 | 0.550 |
Why?
|
| Biomarkers | 10 | 2021 | 2922 | 0.550 |
Why?
|
| Glutathione Synthase | 1 | 2016 | 4 | 0.540 |
Why?
|
| Gene Duplication | 6 | 2011 | 358 | 0.530 |
Why?
|
| Whole Genome Sequencing | 2 | 2020 | 280 | 0.530 |
Why?
|
| Genes, Recessive | 6 | 2022 | 171 | 0.500 |
Why?
|
| Neurodevelopmental Disorders | 4 | 2021 | 458 | 0.490 |
Why?
|
| Bone Diseases, Developmental | 3 | 2017 | 58 | 0.490 |
Why?
|
| Pedigree | 17 | 2022 | 1575 | 0.470 |
Why?
|
| Cathepsin A | 1 | 2014 | 3 | 0.470 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2016 | 174 | 0.470 |
Why?
|
| Dishevelled Proteins | 5 | 2020 | 43 | 0.470 |
Why?
|
| Osteochondrodysplasias | 3 | 2017 | 68 | 0.470 |
Why?
|
| Heterozygote | 8 | 2019 | 679 | 0.460 |
Why?
|
| Membrane Proteins | 8 | 2022 | 1524 | 0.460 |
Why?
|
| Receptor Tyrosine Kinase-like Orphan Receptors | 4 | 2022 | 36 | 0.450 |
Why?
|
| Alleles | 10 | 2021 | 1594 | 0.450 |
Why?
|
| Body Height | 2 | 2018 | 205 | 0.450 |
Why?
|
| Forecasting | 1 | 2015 | 353 | 0.450 |
Why?
|
| Health Planning Guidelines | 3 | 2011 | 31 | 0.440 |
Why?
|
| Trisomy | 4 | 2010 | 104 | 0.430 |
Why?
|
| Uniparental Disomy | 5 | 2005 | 49 | 0.430 |
Why?
|
| Congenital Abnormalities | 1 | 2015 | 242 | 0.410 |
Why?
|
| In Situ Hybridization, Fluorescence | 9 | 2012 | 758 | 0.410 |
Why?
|
| Mutation, Missense | 8 | 2021 | 834 | 0.400 |
Why?
|
| Syndrome | 15 | 2020 | 1117 | 0.390 |
Why?
|
| Malocclusion | 2 | 2022 | 8 | 0.390 |
Why?
|
| Chromosome Aberrations | 6 | 2019 | 617 | 0.390 |
Why?
|
| Retinal Diseases | 4 | 2016 | 170 | 0.390 |
Why?
|
| Chromosome Deletion | 6 | 2012 | 636 | 0.380 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 7 | 2015 | 999 | 0.380 |
Why?
|
| Otorhinolaryngologic Diseases | 1 | 2011 | 9 | 0.380 |
Why?
|
| Chromosome Mapping | 4 | 2011 | 1068 | 0.370 |
Why?
|
| Nucleic Acid Hybridization | 3 | 2008 | 397 | 0.370 |
Why?
|
| Camurati-Engelmann Syndrome | 1 | 2010 | 3 | 0.370 |
Why?
|
| Qualitative Research | 2 | 2024 | 509 | 0.370 |
Why?
|
| Genetic Heterogeneity | 4 | 2020 | 123 | 0.360 |
Why?
|
| Genotype | 13 | 2023 | 2533 | 0.360 |
Why?
|
| Chromosome Banding | 2 | 2008 | 141 | 0.360 |
Why?
|
| DNA Copy Number Variations | 5 | 2018 | 943 | 0.350 |
Why?
|
| Mosaicism | 3 | 2012 | 240 | 0.340 |
Why?
|
| Vascular Malformations | 3 | 2023 | 79 | 0.330 |
Why?
|
| Phenylbutyrates | 2 | 2021 | 54 | 0.330 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2019 | 523 | 0.330 |
Why?
|
| Ectodermal Dysplasia | 1 | 2009 | 43 | 0.330 |
Why?
|
| Carbohydrate Metabolism, Inborn Errors | 2 | 2020 | 37 | 0.320 |
Why?
|
| Chromosomes, Human, X | 5 | 2011 | 156 | 0.320 |
Why?
|
| Noonan Syndrome | 1 | 2008 | 29 | 0.300 |
Why?
|
| Musculoskeletal Abnormalities | 3 | 2019 | 73 | 0.300 |
Why?
|
| Enzyme Replacement Therapy | 2 | 2020 | 17 | 0.300 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2008 | 92 | 0.300 |
Why?
|
| Phenylketonurias | 2 | 2021 | 14 | 0.300 |
Why?
|
| Muscular Diseases | 4 | 2017 | 103 | 0.290 |
Why?
|
| Cleft Lip | 1 | 2009 | 127 | 0.290 |
Why?
|
| Cleft Palate | 1 | 2009 | 140 | 0.290 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2014 | 343 | 0.290 |
Why?
|
| Proteins | 4 | 2015 | 1046 | 0.290 |
Why?
|
| Femur | 2 | 2020 | 58 | 0.290 |
Why?
|
| Wnt Signaling Pathway | 3 | 2020 | 200 | 0.290 |
Why?
|
| Urea | 4 | 2021 | 210 | 0.280 |
Why?
|
| Referral and Consultation | 1 | 2011 | 524 | 0.280 |
Why?
|
| DNA-Binding Proteins | 4 | 2017 | 2036 | 0.280 |
Why?
|
| Haploinsufficiency | 3 | 2021 | 248 | 0.280 |
Why?
|
| Weight Gain | 1 | 2009 | 383 | 0.280 |
Why?
|
| Amniotic Fluid | 4 | 2014 | 147 | 0.280 |
Why?
|
| Middle Aged | 20 | 2024 | 25388 | 0.270 |
Why?
|
| Agenesis of Corpus Callosum | 2 | 2007 | 38 | 0.270 |
Why?
|
| Genetic Diseases, X-Linked | 4 | 2019 | 65 | 0.270 |
Why?
|
| Muscle Hypotonia | 3 | 2016 | 186 | 0.270 |
Why?
|
| Peptide Hormones | 2 | 2017 | 66 | 0.270 |
Why?
|
| Consensus | 2 | 2024 | 604 | 0.270 |
Why?
|
| Cohort Studies | 10 | 2021 | 4635 | 0.260 |
Why?
|
| Wnt-5a Protein | 3 | 2020 | 22 | 0.260 |
Why?
|
| Acyl-CoA Dehydrogenase, Long-Chain | 2 | 2015 | 14 | 0.260 |
Why?
|
| Lipid Metabolism, Inborn Errors | 2 | 2015 | 19 | 0.260 |
Why?
|
| Facial Bones | 1 | 2005 | 28 | 0.260 |
Why?
|
| Choroid Diseases | 1 | 2005 | 21 | 0.250 |
Why?
|
| Mass Screening | 2 | 2021 | 776 | 0.250 |
Why?
|
| Pregnancy | 12 | 2023 | 7071 | 0.250 |
Why?
|
| Enzyme Activation | 3 | 2016 | 620 | 0.250 |
Why?
|
| Microfilament Proteins | 2 | 2017 | 278 | 0.240 |
Why?
|
| Nitrogen | 2 | 2022 | 135 | 0.240 |
Why?
|
| Frameshift Mutation | 2 | 2016 | 175 | 0.240 |
Why?
|
| Chromosomes, Human, Pair 22 | 3 | 2010 | 102 | 0.240 |
Why?
|
| alpha-Mannosidosis | 1 | 2024 | 1 | 0.240 |
Why?
|
| Argininosuccinate Lyase | 2 | 2003 | 60 | 0.240 |
Why?
|
| Fasting | 2 | 2016 | 298 | 0.230 |
Why?
|
| Argininosuccinate Synthase | 2 | 2014 | 20 | 0.230 |
Why?
|
| Genome, Human | 3 | 2019 | 1251 | 0.230 |
Why?
|
| Genetic Therapy | 2 | 2022 | 706 | 0.230 |
Why?
|
| North America | 4 | 2019 | 233 | 0.230 |
Why?
|
| Codon, Nonsense | 5 | 2019 | 131 | 0.230 |
Why?
|
| Platybasia | 1 | 2023 | 1 | 0.230 |
Why?
|
| Mitochondrial Diseases | 2 | 2015 | 133 | 0.230 |
Why?
|
| RNA, Long Noncoding | 3 | 2021 | 210 | 0.220 |
Why?
|
| Spasms, Infantile | 1 | 2005 | 167 | 0.220 |
Why?
|
| Phosphoproteins | 2 | 2016 | 401 | 0.220 |
Why?
|
| Nuclear Proteins | 3 | 2019 | 1281 | 0.220 |
Why?
|
| Bone Development | 2 | 2020 | 57 | 0.220 |
Why?
|
| Prognosis | 6 | 2019 | 4477 | 0.220 |
Why?
|
| Resilience, Psychological | 1 | 2024 | 71 | 0.220 |
Why?
|
| Alcohol Oxidoreductases | 1 | 2003 | 19 | 0.210 |
Why?
|
| Skin | 2 | 2016 | 503 | 0.210 |
Why?
|
| Cross-Sectional Studies | 7 | 2023 | 3286 | 0.210 |
Why?
|
| Delphi Technique | 1 | 2024 | 197 | 0.210 |
Why?
|
| 46, XX Disorders of Sex Development | 1 | 2023 | 22 | 0.210 |
Why?
|
| Phenylalanine | 2 | 2021 | 122 | 0.210 |
Why?
|
| Peptide Fragments | 2 | 2017 | 748 | 0.210 |
Why?
|
| Bone Density Conservation Agents | 1 | 2023 | 51 | 0.210 |
Why?
|
| Chromosome Disorders | 3 | 2019 | 311 | 0.210 |
Why?
|
| Cardiovascular Abnormalities | 1 | 2023 | 51 | 0.210 |
Why?
|
| Gaucher Disease | 1 | 2022 | 12 | 0.210 |
Why?
|
| Interviews as Topic | 1 | 2024 | 368 | 0.210 |
Why?
|
| Exons | 5 | 2018 | 794 | 0.210 |
Why?
|
| Tay-Sachs Disease | 1 | 2002 | 1 | 0.210 |
Why?
|
| Oral Health | 2 | 2020 | 17 | 0.210 |
Why?
|
| Repressor Proteins | 2 | 2015 | 810 | 0.200 |
Why?
|
| Glypicans | 2 | 2020 | 39 | 0.200 |
Why?
|
| Sequence Deletion | 5 | 2016 | 526 | 0.200 |
Why?
|
| Apyrase | 1 | 2022 | 18 | 0.200 |
Why?
|
| Sodium-Calcium Exchanger | 1 | 2022 | 21 | 0.200 |
Why?
|
| Pain Management | 1 | 2024 | 166 | 0.200 |
Why?
|
| Spastic Paraplegia, Hereditary | 1 | 2022 | 29 | 0.200 |
Why?
|
| Chronic Pain | 1 | 2024 | 116 | 0.200 |
Why?
|
| Hypospadias | 2 | 2014 | 80 | 0.200 |
Why?
|
| Androgen-Insensitivity Syndrome | 2 | 2015 | 28 | 0.200 |
Why?
|
| Comparative Genomic Hybridization | 6 | 2020 | 576 | 0.200 |
Why?
|
| Hydroxocobalamin | 2 | 2018 | 9 | 0.190 |
Why?
|
| Phenylalanine Hydroxylase | 1 | 2021 | 14 | 0.190 |
Why?
|
| Metabolome | 2 | 2022 | 287 | 0.190 |
Why?
|
| Coat Protein Complex I | 1 | 2021 | 14 | 0.190 |
Why?
|
| Surveys and Questionnaires | 5 | 2024 | 3619 | 0.190 |
Why?
|
| Epilepsy, Generalized | 1 | 2022 | 64 | 0.190 |
Why?
|
| Base Sequence | 10 | 2017 | 3114 | 0.190 |
Why?
|
| Sarcoma, Ewing | 1 | 2022 | 112 | 0.190 |
Why?
|
| Coatomer Protein | 1 | 2021 | 30 | 0.190 |
Why?
|
| Acyltransferases | 3 | 2016 | 46 | 0.190 |
Why?
|
| Mice | 13 | 2023 | 17494 | 0.190 |
Why?
|
| Brain | 5 | 2021 | 2944 | 0.190 |
Why?
|
| Telomere | 1 | 2002 | 207 | 0.190 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2016 | 864 | 0.190 |
Why?
|
| Psychomotor Disorders | 2 | 2017 | 28 | 0.190 |
Why?
|
| Hypertelorism | 1 | 2020 | 12 | 0.190 |
Why?
|
| Mouth Abnormalities | 1 | 2020 | 15 | 0.180 |
Why?
|
| Adaptation, Psychological | 1 | 2024 | 458 | 0.180 |
Why?
|
| Anemia, Macrocytic | 1 | 2020 | 8 | 0.180 |
Why?
|
| Bulbar Palsy, Progressive | 1 | 2020 | 8 | 0.180 |
Why?
|
| Osteosclerosis | 1 | 2020 | 12 | 0.180 |
Why?
|
| Glutamine | 2 | 2022 | 194 | 0.180 |
Why?
|
| Transaldolase | 1 | 2020 | 4 | 0.180 |
Why?
|
| Riboflavin Deficiency | 1 | 2020 | 9 | 0.180 |
Why?
|
| Vitamin B 12 Deficiency | 2 | 2018 | 39 | 0.180 |
Why?
|
| Transketolase | 1 | 2020 | 19 | 0.180 |
Why?
|
| Aspartate Carbamoyltransferase | 1 | 2020 | 6 | 0.180 |
Why?
|
| Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing) | 1 | 2020 | 6 | 0.180 |
Why?
|
| Chromatography, Liquid | 2 | 2020 | 188 | 0.180 |
Why?
|
| Seizures | 5 | 2022 | 874 | 0.180 |
Why?
|
| Sleep Apnea Syndromes | 2 | 2014 | 71 | 0.180 |
Why?
|
| Riboflavin | 1 | 2020 | 37 | 0.180 |
Why?
|
| Fibrillar Collagens | 1 | 2020 | 15 | 0.180 |
Why?
|
| Aconitate Hydratase | 1 | 2020 | 11 | 0.180 |
Why?
|
| Osteoporosis | 1 | 2021 | 114 | 0.180 |
Why?
|
| Oxidoreductases | 1 | 2020 | 92 | 0.180 |
Why?
|
| Founder Effect | 1 | 2020 | 31 | 0.180 |
Why?
|
| Mucopolysaccharidosis VII | 1 | 2020 | 2 | 0.180 |
Why?
|
| Vesicular Transport Proteins | 1 | 2021 | 117 | 0.180 |
Why?
|
| Disease Progression | 3 | 2018 | 1970 | 0.180 |
Why?
|
| Facies | 3 | 2016 | 155 | 0.170 |
Why?
|
| Genes, X-Linked | 2 | 2016 | 59 | 0.170 |
Why?
|
| Glycosaminoglycans | 1 | 2020 | 36 | 0.170 |
Why?
|
| Neurocognitive Disorders | 1 | 2020 | 67 | 0.170 |
Why?
|
| Amino Acid Sequence | 9 | 2019 | 2677 | 0.170 |
Why?
|
| Glucuronidase | 1 | 2020 | 32 | 0.170 |
Why?
|
| GTP-Binding Protein beta Subunits | 2 | 2017 | 31 | 0.170 |
Why?
|
| Fetal Alcohol Spectrum Disorders | 1 | 2019 | 12 | 0.170 |
Why?
|
| Hip Dislocation | 1 | 2020 | 26 | 0.170 |
Why?
|
| Diet | 3 | 2022 | 1099 | 0.170 |
Why?
|
| Optic Atrophy | 1 | 2020 | 47 | 0.170 |
Why?
|
| White Matter | 1 | 2022 | 181 | 0.170 |
Why?
|
| Hand Deformities, Congenital | 1 | 2020 | 89 | 0.170 |
Why?
|
| Metalloendopeptidases | 2 | 2017 | 96 | 0.170 |
Why?
|
| Quality of Life | 5 | 2021 | 1897 | 0.170 |
Why?
|
| Early Diagnosis | 2 | 2018 | 178 | 0.170 |
Why?
|
| Lower Extremity Deformities, Congenital | 1 | 2019 | 9 | 0.170 |
Why?
|
| Sex Reassignment Procedures | 2 | 2016 | 18 | 0.160 |
Why?
|
| Dental Caries | 1 | 2019 | 10 | 0.160 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2019 | 2576 | 0.160 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 4987 | 0.160 |
Why?
|
| Mobility Limitation | 1 | 2019 | 22 | 0.160 |
Why?
|
| Radiography | 4 | 2015 | 797 | 0.160 |
Why?
|
| Wnt Proteins | 2 | 2016 | 199 | 0.160 |
Why?
|
| Educational Measurement | 1 | 2012 | 320 | 0.160 |
Why?
|
| Molecular Sequence Data | 8 | 2016 | 3870 | 0.160 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2020 | 135 | 0.160 |
Why?
|
| RNA Helicases | 1 | 2019 | 63 | 0.160 |
Why?
|
| Virilism | 1 | 2018 | 14 | 0.160 |
Why?
|
| Anemia, Megaloblastic | 1 | 2018 | 4 | 0.160 |
Why?
|
| Deafness | 1 | 2019 | 80 | 0.160 |
Why?
|
| Hearing Loss | 1 | 2019 | 132 | 0.160 |
Why?
|
| Carnitine | 2 | 2015 | 78 | 0.160 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2019 | 116 | 0.160 |
Why?
|
| N-Terminal Acetyltransferase A | 1 | 2018 | 8 | 0.150 |
Why?
|
| N-Terminal Acetyltransferase E | 1 | 2018 | 8 | 0.150 |
Why?
|
| Gene Rearrangement | 2 | 2011 | 316 | 0.150 |
Why?
|
| Disease Management | 3 | 2017 | 511 | 0.150 |
Why?
|
| Transcription Factors | 4 | 2019 | 2586 | 0.150 |
Why?
|
| Zellweger Syndrome | 1 | 2018 | 10 | 0.150 |
Why?
|
| Phosphoglycerate Dehydrogenase | 1 | 2017 | 5 | 0.150 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 161 | 0.150 |
Why?
|
| Pediatrics | 2 | 2019 | 1137 | 0.150 |
Why?
|
| Bone Neoplasms | 1 | 2022 | 424 | 0.150 |
Why?
|
| Peroxisomal Disorders | 1 | 2018 | 13 | 0.150 |
Why?
|
| Phosphatidylcholines | 1 | 2017 | 41 | 0.150 |
Why?
|
| Transaminases | 1 | 2017 | 33 | 0.150 |
Why?
|
| Lipoma | 2 | 2014 | 23 | 0.150 |
Why?
|
| Phenylacetates | 1 | 2017 | 23 | 0.150 |
Why?
|
| Severity of Illness Index | 4 | 2021 | 2794 | 0.150 |
Why?
|
| Liver Transplantation | 2 | 2019 | 1030 | 0.150 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2018 | 52 | 0.150 |
Why?
|
| Appetite Regulation | 1 | 2017 | 36 | 0.150 |
Why?
|
| Nevus | 2 | 2014 | 36 | 0.150 |
Why?
|
| Homocystinuria | 1 | 2017 | 21 | 0.150 |
Why?
|
| Cell Cycle Proteins | 2 | 2019 | 660 | 0.140 |
Why?
|
| Fibronectins | 1 | 2017 | 111 | 0.140 |
Why?
|
| Diphosphonates | 3 | 2023 | 37 | 0.140 |
Why?
|
| Mobius Syndrome | 1 | 2017 | 8 | 0.140 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 1 | 2022 | 379 | 0.140 |
Why?
|
| Animals | 16 | 2023 | 33670 | 0.140 |
Why?
|
| Serine | 1 | 2017 | 174 | 0.140 |
Why?
|
| Tubulin | 1 | 2017 | 99 | 0.140 |
Why?
|
| Neuropsychological Tests | 1 | 2020 | 920 | 0.140 |
Why?
|
| 3-Hydroxyacyl CoA Dehydrogenases | 2 | 2009 | 10 | 0.140 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2019 | 549 | 0.140 |
Why?
|
| 3-Oxo-5-alpha-Steroid 4-Dehydrogenase | 1 | 2016 | 3 | 0.140 |
Why?
|
| Glycine | 1 | 2017 | 164 | 0.140 |
Why?
|
| Cell Cycle | 1 | 2019 | 617 | 0.140 |
Why?
|
| Isoleucine | 2 | 2009 | 27 | 0.140 |
Why?
|
| Signal Transduction | 6 | 2023 | 4504 | 0.140 |
Why?
|
| Cesarean Section | 2 | 2021 | 379 | 0.140 |
Why?
|
| Psychometrics | 1 | 2020 | 666 | 0.140 |
Why?
|
| Fibroblasts | 3 | 2021 | 874 | 0.140 |
Why?
|
| Genetics | 1 | 2016 | 23 | 0.140 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2017 | 168 | 0.140 |
Why?
|
| Sudden Infant Death | 1 | 2016 | 33 | 0.140 |
Why?
|
| Amino Acid Substitution | 2 | 2016 | 389 | 0.140 |
Why?
|
| Citrulline | 2 | 2014 | 84 | 0.140 |
Why?
|
| Sinoatrial Node | 1 | 2016 | 24 | 0.140 |
Why?
|
| Gonadal Dysgenesis, 46,XY | 1 | 2016 | 17 | 0.130 |
Why?
|
| Bradycardia | 1 | 2016 | 62 | 0.130 |
Why?
|
| Autopsy | 1 | 2016 | 114 | 0.130 |
Why?
|
| Carrier Proteins | 3 | 2023 | 1022 | 0.130 |
Why?
|
| Hypothalamus | 1 | 2017 | 213 | 0.130 |
Why?
|
| Congenital Disorders of Glycosylation | 1 | 2016 | 38 | 0.130 |
Why?
|
| X Chromosome Inactivation | 3 | 2016 | 63 | 0.130 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2016 | 53 | 0.130 |
Why?
|
| Genes | 1 | 1997 | 443 | 0.130 |
Why?
|
| Androgens | 2 | 2015 | 257 | 0.130 |
Why?
|
| United States | 7 | 2020 | 10415 | 0.130 |
Why?
|
| Chondroitinsulfatases | 1 | 2015 | 2 | 0.130 |
Why?
|
| Mucopolysaccharidosis IV | 1 | 2015 | 2 | 0.130 |
Why?
|
| History, 21st Century | 1 | 2016 | 266 | 0.130 |
Why?
|
| Dopa Decarboxylase | 1 | 2015 | 7 | 0.130 |
Why?
|
| Ornithine Carbamoyltransferase Deficiency Disease | 2 | 2017 | 28 | 0.130 |
Why?
|
| Aromatic-L-Amino-Acid Decarboxylases | 1 | 2015 | 17 | 0.120 |
Why?
|
| Fetus | 3 | 2014 | 580 | 0.120 |
Why?
|
| Liver | 4 | 2021 | 1850 | 0.120 |
Why?
|
| Evidence-Based Practice | 1 | 2016 | 107 | 0.120 |
Why?
|
| Hand | 2 | 2020 | 101 | 0.120 |
Why?
|
| Acidosis | 1 | 2016 | 92 | 0.120 |
Why?
|
| Genes, Dominant | 3 | 2020 | 246 | 0.120 |
Why?
|
| Neoplasm Proteins | 1 | 2019 | 670 | 0.120 |
Why?
|
| History, 20th Century | 1 | 2016 | 381 | 0.120 |
Why?
|
| De Lange Syndrome | 1 | 2015 | 44 | 0.120 |
Why?
|
| Eye | 1 | 2016 | 227 | 0.120 |
Why?
|
| Glutathione | 1 | 2016 | 194 | 0.120 |
Why?
|
| Retrospective Studies | 10 | 2020 | 15601 | 0.120 |
Why?
|
| Body Weight | 1 | 2018 | 964 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2015 | 150 | 0.110 |
Why?
|
| Dietary Supplements | 1 | 2017 | 457 | 0.110 |
Why?
|
| T-Box Domain Proteins | 1 | 2015 | 117 | 0.110 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2017 | 468 | 0.110 |
Why?
|
| Child Development | 1 | 2016 | 249 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 17 | 2 | 2020 | 370 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2022 | 467 | 0.110 |
Why?
|
| Mass Spectrometry | 3 | 2020 | 323 | 0.110 |
Why?
|
| Point Mutation | 2 | 2009 | 346 | 0.110 |
Why?
|
| Argininosuccinic Acid | 1 | 2003 | 6 | 0.110 |
Why?
|
| Cellular Reprogramming | 1 | 2014 | 114 | 0.110 |
Why?
|
| Homozygote | 3 | 2020 | 533 | 0.110 |
Why?
|
| Adipose Tissue | 2 | 2014 | 446 | 0.110 |
Why?
|
| Dependovirus | 1 | 2013 | 123 | 0.100 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2014 | 191 | 0.100 |
Why?
|
| Connective Tissue | 1 | 2012 | 20 | 0.100 |
Why?
|
| Arthrogryposis | 1 | 2012 | 33 | 0.100 |
Why?
|
| Tacrolimus Binding Proteins | 1 | 2012 | 66 | 0.100 |
Why?
|
| Pupil Disorders | 1 | 2012 | 18 | 0.100 |
Why?
|
| Computational Biology | 1 | 2017 | 793 | 0.100 |
Why?
|
| Maple Syrup Urine Disease | 1 | 2012 | 15 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2012 | 59 | 0.100 |
Why?
|
| Endocrinology | 1 | 2014 | 139 | 0.100 |
Why?
|
| Coffin-Lowry Syndrome | 1 | 2011 | 3 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 5 | 2020 | 4333 | 0.100 |
Why?
|
| Biological Clocks | 1 | 2012 | 28 | 0.100 |
Why?
|
| Failure to Thrive | 3 | 2019 | 91 | 0.100 |
Why?
|
| Cardiomyopathy, Restrictive | 1 | 2011 | 21 | 0.100 |
Why?
|
| Lysine | 1 | 2012 | 200 | 0.100 |
Why?
|
| Skull | 2 | 2022 | 143 | 0.100 |
Why?
|
| Internship and Residency | 1 | 2012 | 1149 | 0.100 |
Why?
|
| Eye Abnormalities | 1 | 2012 | 108 | 0.100 |
Why?
|
| Risk Assessment | 3 | 2018 | 3222 | 0.100 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2011 | 89 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 2 | 2016 | 1240 | 0.090 |
Why?
|
| Inheritance Patterns | 2 | 2009 | 124 | 0.090 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 2011 | 20 | 0.090 |
Why?
|
| Nervous System | 1 | 2011 | 129 | 0.090 |
Why?
|
| Optic Nerve Diseases | 1 | 2012 | 87 | 0.090 |
Why?
|
| Gastrostomy | 1 | 2011 | 84 | 0.090 |
Why?
|
| Upper Extremity | 1 | 2011 | 42 | 0.090 |
Why?
|
| Arteriovenous Malformations | 1 | 2011 | 46 | 0.090 |
Why?
|
| Aged | 5 | 2024 | 18464 | 0.090 |
Why?
|
| Certification | 1 | 2011 | 69 | 0.090 |
Why?
|
| Global Health | 1 | 2015 | 554 | 0.090 |
Why?
|
| Cell Line | 4 | 2020 | 2787 | 0.090 |
Why?
|
| Internet | 1 | 2013 | 372 | 0.090 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2011 | 129 | 0.090 |
Why?
|
| Recurrence | 2 | 2011 | 1393 | 0.090 |
Why?
|
| Patient Rights | 1 | 2010 | 48 | 0.090 |
Why?
|
| Gene Dosage | 2 | 2009 | 441 | 0.090 |
Why?
|
| Gene Expression Regulation | 2 | 2018 | 2536 | 0.090 |
Why?
|
| Treatment Outcome | 7 | 2024 | 11685 | 0.090 |
Why?
|
| Sex Chromosome Aberrations | 1 | 2009 | 57 | 0.080 |
Why?
|
| Age of Onset | 3 | 2020 | 574 | 0.080 |
Why?
|
| Sensitivity and Specificity | 3 | 2015 | 2007 | 0.080 |
Why?
|
| Sirolimus | 1 | 2011 | 221 | 0.080 |
Why?
|
| Cross-Over Studies | 2 | 2021 | 302 | 0.080 |
Why?
|
| Foot | 1 | 2009 | 60 | 0.080 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 3 | 2014 | 74 | 0.080 |
Why?
|
| Huntington Disease | 1 | 2010 | 140 | 0.080 |
Why?
|
| DNA Mutational Analysis | 5 | 2012 | 791 | 0.080 |
Why?
|
| Anthropometry | 1 | 2009 | 189 | 0.080 |
Why?
|
| Eyelids | 1 | 2009 | 114 | 0.080 |
Why?
|
| Transcriptome | 1 | 2015 | 901 | 0.080 |
Why?
|
| Pilot Projects | 3 | 2019 | 1357 | 0.080 |
Why?
|
| Sequence Homology, Amino Acid | 3 | 2019 | 654 | 0.080 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 2008 | 25 | 0.080 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2008 | 22 | 0.080 |
Why?
|
| Heart Defects, Congenital | 2 | 2016 | 1801 | 0.080 |
Why?
|
| Steroids | 1 | 2009 | 201 | 0.080 |
Why?
|
| Trans-Activators | 2 | 2009 | 802 | 0.080 |
Why?
|
| Disclosure | 3 | 2016 | 153 | 0.080 |
Why?
|
| Software | 1 | 2013 | 671 | 0.080 |
Why?
|
| Health Status | 1 | 2010 | 369 | 0.080 |
Why?
|
| Databases, Factual | 1 | 2013 | 1138 | 0.080 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2008 | 32 | 0.080 |
Why?
|
| Forkhead Transcription Factors | 1 | 2010 | 369 | 0.070 |
Why?
|
| Human Growth Hormone | 1 | 2008 | 74 | 0.070 |
Why?
|
| Serpins | 2 | 1998 | 27 | 0.070 |
Why?
|
| Family Health | 2 | 2007 | 258 | 0.070 |
Why?
|
| Siblings | 2 | 2007 | 193 | 0.070 |
Why?
|
| Incidence | 1 | 2015 | 2992 | 0.070 |
Why?
|
| RNA Splice Sites | 2 | 2022 | 87 | 0.070 |
Why?
|
| Prader-Willi Syndrome | 1 | 2008 | 66 | 0.070 |
Why?
|
| Spine | 2 | 2020 | 148 | 0.070 |
Why?
|
| Capillaries | 1 | 2007 | 69 | 0.070 |
Why?
|
| DiGeorge Syndrome | 1 | 2008 | 80 | 0.070 |
Why?
|
| Nervous System Malformations | 1 | 2009 | 126 | 0.070 |
Why?
|
| Decision Making | 2 | 2010 | 651 | 0.070 |
Why?
|
| Fibrillin-1 | 2 | 2017 | 58 | 0.070 |
Why?
|
| Heart Ventricles | 1 | 2011 | 766 | 0.070 |
Why?
|
| Serine Endopeptidases | 2 | 1998 | 176 | 0.070 |
Why?
|
| Emergency Medical Services | 1 | 2011 | 430 | 0.070 |
Why?
|
| Databases, Genetic | 2 | 2019 | 469 | 0.070 |
Why?
|
| Zebrafish | 2 | 2021 | 372 | 0.070 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 1998 | 505 | 0.070 |
Why?
|
| DNA Methylation | 2 | 2019 | 988 | 0.070 |
Why?
|
| CCCTC-Binding Factor | 1 | 2005 | 20 | 0.070 |
Why?
|
| Consensus Sequence | 1 | 2005 | 58 | 0.070 |
Why?
|
| Health Surveys | 1 | 2007 | 235 | 0.060 |
Why?
|
| Fertilization in Vitro | 1 | 2007 | 188 | 0.060 |
Why?
|
| Recombinant Proteins | 4 | 2016 | 1368 | 0.060 |
Why?
|
| Ammonia | 2 | 2017 | 68 | 0.060 |
Why?
|
| Body Composition | 1 | 2008 | 472 | 0.060 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2012 | 622 | 0.060 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2005 | 167 | 0.060 |
Why?
|
| Pregnancy Complications | 1 | 2010 | 502 | 0.060 |
Why?
|
| Sexual Development | 2 | 2019 | 23 | 0.060 |
Why?
|
| Argininosuccinic Aciduria | 2 | 2017 | 47 | 0.060 |
Why?
|
| ATPases Associated with Diverse Cellular Activities | 2 | 2017 | 67 | 0.060 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2017 | 225 | 0.060 |
Why?
|
| Binding Sites | 2 | 2005 | 1291 | 0.060 |
Why?
|
| Patient Care Team | 1 | 2009 | 538 | 0.060 |
Why?
|
| Nerve Tissue Proteins | 1 | 2010 | 1112 | 0.060 |
Why?
|
| NIH 3T3 Cells | 1 | 2023 | 92 | 0.060 |
Why?
|
| Teriparatide | 1 | 2023 | 7 | 0.060 |
Why?
|
| Body Mass Index | 3 | 2018 | 1457 | 0.060 |
Why?
|
| Neurons | 3 | 2017 | 1916 | 0.050 |
Why?
|
| Fracture Fixation | 1 | 2023 | 24 | 0.050 |
Why?
|
| Malformations of Cortical Development | 2 | 2017 | 53 | 0.050 |
Why?
|
| Self Efficacy | 1 | 2024 | 191 | 0.050 |
Why?
|
| Prevalence | 3 | 2019 | 2370 | 0.050 |
Why?
|
| Epilepsies, Myoclonic | 1 | 2003 | 24 | 0.050 |
Why?
|
| Blindness, Cortical | 1 | 2003 | 15 | 0.050 |
Why?
|
| Estriol | 1 | 2002 | 7 | 0.050 |
Why?
|
| Organ Specificity | 2 | 2014 | 426 | 0.050 |
Why?
|
| Acids | 1 | 2003 | 28 | 0.050 |
Why?
|
| Arylsulfatases | 1 | 2002 | 22 | 0.050 |
Why?
|
| Growth Disorders | 3 | 2002 | 209 | 0.050 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2024 | 122 | 0.050 |
Why?
|
| Enzyme Therapy | 1 | 2022 | 5 | 0.050 |
Why?
|
| Hyperplasia | 2 | 2014 | 214 | 0.050 |
Why?
|
| Phosphatidylinositols | 1 | 2022 | 32 | 0.050 |
Why?
|
| Ifosfamide | 1 | 2022 | 37 | 0.050 |
Why?
|
| Epilepsy | 1 | 2010 | 852 | 0.050 |
Why?
|
| Uncertainty | 1 | 2023 | 98 | 0.050 |
Why?
|
| Dysarthria | 1 | 2022 | 21 | 0.050 |
Why?
|
| Jews | 1 | 2002 | 31 | 0.050 |
Why?
|
| Etoposide | 1 | 2022 | 119 | 0.050 |
Why?
|
| Rett Syndrome | 1 | 2005 | 277 | 0.050 |
Why?
|
| Eye Movements | 1 | 2022 | 70 | 0.050 |
Why?
|
| Microsatellite Repeats | 1 | 2003 | 218 | 0.050 |
Why?
|
| Sequence Alignment | 2 | 2016 | 615 | 0.050 |
Why?
|
| Sex Factors | 2 | 2019 | 1226 | 0.050 |
Why?
|
| Histidine | 1 | 2022 | 72 | 0.050 |
Why?
|
| Caenorhabditis elegans | 1 | 2023 | 221 | 0.050 |
Why?
|
| Paraplegia | 1 | 2022 | 86 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 1 | 2005 | 1357 | 0.050 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2022 | 149 | 0.050 |
Why?
|
| Fear | 1 | 2023 | 198 | 0.050 |
Why?
|
| Family Characteristics | 1 | 2002 | 76 | 0.050 |
Why?
|
| Acetylgalactosamine | 1 | 2021 | 10 | 0.050 |
Why?
|
| Vincristine | 1 | 2022 | 207 | 0.050 |
Why?
|
| Disease Models, Animal | 3 | 2021 | 4278 | 0.050 |
Why?
|
| DNA, Complementary | 1 | 2022 | 459 | 0.050 |
Why?
|
| Diet, Protein-Restricted | 1 | 2003 | 82 | 0.050 |
Why?
|
| Lumbar Vertebrae | 1 | 2022 | 106 | 0.050 |
Why?
|
| Molecular Chaperones | 1 | 2022 | 169 | 0.050 |
Why?
|
| Models, Animal | 1 | 2003 | 465 | 0.050 |
Why?
|
| Obesity | 1 | 2012 | 2082 | 0.050 |
Why?
|
| Ascorbic Acid | 1 | 2021 | 78 | 0.050 |
Why?
|
| Golgi Apparatus | 1 | 2021 | 91 | 0.050 |
Why?
|
| Meglutol | 1 | 2001 | 2 | 0.050 |
Why?
|
| Down-Regulation | 1 | 2023 | 700 | 0.050 |
Why?
|
| Glutarates | 1 | 2001 | 27 | 0.050 |
Why?
|
| Doxorubicin | 1 | 2022 | 306 | 0.050 |
Why?
|
| Embryo, Nonmammalian | 1 | 2021 | 141 | 0.050 |
Why?
|
| Canada | 1 | 2012 | 293 | 0.050 |
Why?
|
| Plasma Membrane Neurotransmitter Transport Proteins | 1 | 2020 | 7 | 0.050 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2023 | 429 | 0.050 |
Why?
|
| Ataxia | 1 | 2022 | 168 | 0.050 |
Why?
|
| Nucleic Acid Conformation | 1 | 2021 | 185 | 0.050 |
Why?
|
| Mitochondrial Encephalomyopathies | 1 | 2001 | 27 | 0.050 |
Why?
|
| Brain Diseases, Metabolic, Inborn | 1 | 2020 | 23 | 0.050 |
Why?
|
| Creatine | 1 | 2020 | 41 | 0.050 |
Why?
|
| Dihydroorotase | 1 | 2020 | 6 | 0.050 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2020 | 44 | 0.040 |
Why?
|
| Uridine | 1 | 2020 | 34 | 0.040 |
Why?
|
| Endoplasmic Reticulum | 1 | 2021 | 213 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2022 | 422 | 0.040 |
Why?
|
| Extremities | 1 | 2020 | 82 | 0.040 |
Why?
|
| Proteomics | 1 | 2023 | 474 | 0.040 |
Why?
|
| Absorptiometry, Photon | 1 | 2020 | 170 | 0.040 |
Why?
|
| Consanguinity | 1 | 2020 | 106 | 0.040 |
Why?
|
| Infant Mortality | 1 | 2021 | 174 | 0.040 |
Why?
|
| Genomic Structural Variation | 1 | 2020 | 78 | 0.040 |
Why?
|
| Hepatocytes | 1 | 2021 | 249 | 0.040 |
Why?
|
| Mice, Knockout | 2 | 2021 | 3762 | 0.040 |
Why?
|
| Liver Function Tests | 1 | 2019 | 103 | 0.040 |
Why?
|
| China | 1 | 2020 | 227 | 0.040 |
Why?
|
| DNA, Mitochondrial | 1 | 2001 | 209 | 0.040 |
Why?
|
| Amino Acids | 1 | 2022 | 661 | 0.040 |
Why?
|
| Mental Retardation, X-Linked | 1 | 2020 | 102 | 0.040 |
Why?
|
| Transforming Growth Factor beta | 1 | 2022 | 460 | 0.040 |
Why?
|
| RNA, Small Interfering | 1 | 2021 | 660 | 0.040 |
Why?
|
| Cognition | 1 | 2024 | 732 | 0.040 |
Why?
|
| Sequence Homology | 1 | 2019 | 63 | 0.040 |
Why?
|
| Blood-Brain Barrier | 1 | 2020 | 141 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 2020 | 230 | 0.040 |
Why?
|
| Informed Consent | 2 | 2015 | 339 | 0.040 |
Why?
|
| Uterus | 1 | 2023 | 591 | 0.040 |
Why?
|
| Hematologic Tests | 1 | 2018 | 34 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2019 | 129 | 0.040 |
Why?
|
| Hormones | 1 | 2019 | 189 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2020 | 707 | 0.040 |
Why?
|
| Elastin | 1 | 1998 | 31 | 0.040 |
Why?
|
| Sphingomyelins | 1 | 2018 | 16 | 0.040 |
Why?
|
| Williams Syndrome | 1 | 1998 | 39 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 1998 | 73 | 0.040 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2020 | 286 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2019 | 3433 | 0.040 |
Why?
|
| Blood Chemical Analysis | 1 | 2018 | 77 | 0.040 |
Why?
|
| Injections, Intramuscular | 1 | 2018 | 192 | 0.040 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2021 | 311 | 0.040 |
Why?
|
| Appetite Depressants | 1 | 2017 | 20 | 0.040 |
Why?
|
| Infant Care | 1 | 2017 | 46 | 0.040 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2019 | 184 | 0.040 |
Why?
|
| Chromosome Segregation | 1 | 2017 | 58 | 0.040 |
Why?
|
| Gene Deletion | 2 | 2016 | 799 | 0.040 |
Why?
|
| Cartilage | 1 | 2017 | 46 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2017 | 59 | 0.040 |
Why?
|
| DNA Primers | 2 | 2015 | 667 | 0.040 |
Why?
|
| Age Factors | 2 | 2019 | 2769 | 0.040 |
Why?
|
| Glycerol | 1 | 2017 | 91 | 0.040 |
Why?
|
| Ultrasonography, Prenatal | 1 | 2023 | 901 | 0.040 |
Why?
|
| Protein Binding | 1 | 2021 | 1734 | 0.040 |
Why?
|
| Muridae | 1 | 1997 | 16 | 0.040 |
Why?
|
| DNA Replication | 1 | 2019 | 345 | 0.040 |
Why?
|
| Risk Factors | 3 | 2019 | 9677 | 0.040 |
Why?
|
| Facial Paralysis | 1 | 2017 | 37 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 1997 | 139 | 0.040 |
Why?
|
| Eye Diseases, Hereditary | 1 | 2017 | 33 | 0.040 |
Why?
|
| Muscle, Skeletal | 2 | 2019 | 923 | 0.030 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 1997 | 142 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 262 | 0.030 |
Why?
|
| Ocular Motility Disorders | 1 | 2017 | 38 | 0.030 |
Why?
|
| Ophthalmoplegia | 1 | 2017 | 55 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2016 | 101 | 0.030 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2021 | 996 | 0.030 |
Why?
|
| Consent Forms | 1 | 2016 | 24 | 0.030 |
Why?
|
| Coroners and Medical Examiners | 1 | 2016 | 16 | 0.030 |
Why?
|
| Diagnosis, Differential | 2 | 2017 | 1872 | 0.030 |
Why?
|
| Texas | 2 | 2017 | 3521 | 0.030 |
Why?
|
| Glutamic Acid | 1 | 2017 | 200 | 0.030 |
Why?
|
| Motor Activity | 1 | 2019 | 507 | 0.030 |
Why?
|
| Progeria | 1 | 2016 | 16 | 0.030 |
Why?
|
| Glycosylation | 1 | 2016 | 111 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2014 | 3069 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2018 | 301 | 0.030 |
Why?
|
| Mice, Obese | 1 | 2016 | 77 | 0.030 |
Why?
|
| Family | 1 | 2019 | 569 | 0.030 |
Why?
|
| Orbital Diseases | 1 | 2017 | 91 | 0.030 |
Why?
|
| Choanal Atresia | 1 | 2016 | 18 | 0.030 |
Why?
|
| Tretinoin | 1 | 2016 | 117 | 0.030 |
Why?
|
| Adenosine Triphosphatases | 1 | 2017 | 210 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2020 | 447 | 0.030 |
Why?
|
| Protein Array Analysis | 1 | 2016 | 101 | 0.030 |
Why?
|
| Species Specificity | 1 | 1997 | 550 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 1998 | 679 | 0.030 |
Why?
|
| Keratan Sulfate | 1 | 2015 | 7 | 0.030 |
Why?
|
| Zebrafish Proteins | 1 | 2016 | 105 | 0.030 |
Why?
|
| Confidentiality | 1 | 2016 | 103 | 0.030 |
Why?
|
| Adipose Tissue, White | 1 | 2016 | 78 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 1248 | 0.030 |
Why?
|
| Pathology, Molecular | 1 | 2015 | 60 | 0.030 |
Why?
|
| Dihydroxyphenylalanine | 1 | 2015 | 8 | 0.030 |
Why?
|
| Mitochondrial Proteins | 1 | 2017 | 240 | 0.030 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2016 | 160 | 0.030 |
Why?
|
| Gene Components | 1 | 2015 | 7 | 0.030 |
Why?
|
| Cyclic AMP | 1 | 2016 | 249 | 0.030 |
Why?
|
| Heart Function Tests | 1 | 2015 | 57 | 0.030 |
Why?
|
| Genitalia | 1 | 2015 | 35 | 0.030 |
Why?
|
| Gonads | 1 | 2015 | 37 | 0.030 |
Why?
|
| Genetic Carrier Screening | 1 | 2015 | 76 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2017 | 740 | 0.030 |
Why?
|
| Exonucleases | 1 | 2015 | 23 | 0.030 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2018 | 416 | 0.030 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 1 | 2015 | 28 | 0.030 |
Why?
|
| Genome-Wide Association Study | 2 | 2015 | 1631 | 0.030 |
Why?
|
| Tyrosine | 1 | 2015 | 167 | 0.030 |
Why?
|
| Puberty | 1 | 2015 | 94 | 0.030 |
Why?
|
| Receptors, Androgen | 2 | 2009 | 408 | 0.030 |
Why?
|
| Muscle Strength | 1 | 2015 | 70 | 0.030 |
Why?
|
| Cell Shape | 1 | 2014 | 61 | 0.030 |
Why?
|
| Respiratory Function Tests | 1 | 2015 | 194 | 0.030 |
Why?
|
| Viral Proteins | 1 | 1996 | 349 | 0.030 |
Why?
|
| Antibodies | 1 | 2016 | 383 | 0.030 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2015 | 62 | 0.030 |
Why?
|
| Rats | 2 | 2017 | 3653 | 0.030 |
Why?
|
| Histone Deacetylases | 1 | 2015 | 115 | 0.030 |
Why?
|
| Fetal Growth Retardation | 1 | 2016 | 216 | 0.030 |
Why?
|
| Exercise Test | 1 | 2015 | 247 | 0.030 |
Why?
|
| Cell Transdifferentiation | 1 | 2014 | 67 | 0.030 |
Why?
|
| Thyroxine-Binding Globulin | 1 | 2013 | 1 | 0.030 |
Why?
|
| Circadian Rhythm | 1 | 2016 | 268 | 0.030 |
Why?
|
| Hypoglycemia | 1 | 2015 | 191 | 0.030 |
Why?
|
| Birth Weight | 1 | 2015 | 333 | 0.030 |
Why?
|
| Transduction, Genetic | 1 | 2014 | 297 | 0.030 |
Why?
|
| Heart Rate | 1 | 2016 | 583 | 0.030 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2015 | 154 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2017 | 1612 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 2 | 2010 | 1591 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 728 | 0.030 |
Why?
|
| Ethics, Medical | 1 | 2016 | 395 | 0.030 |
Why?
|
| Gastroesophageal Reflux | 1 | 2016 | 288 | 0.030 |
Why?
|
| Walking | 1 | 2015 | 197 | 0.030 |
Why?
|
| Osteopetrosis | 1 | 2013 | 13 | 0.030 |
Why?
|
| Carbamoyl-Phosphate Synthase (Ammonia) | 1 | 2003 | 6 | 0.030 |
Why?
|
| Ornithine Carbamoyltransferase | 1 | 2003 | 13 | 0.030 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2015 | 214 | 0.030 |
Why?
|
| Glycoproteins | 2 | 2007 | 371 | 0.030 |
Why?
|
| Arginase | 1 | 2003 | 28 | 0.030 |
Why?
|
| Hydroxylation | 1 | 2012 | 45 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 1976 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2015 | 605 | 0.030 |
Why?
|
| Cyclic GMP | 1 | 2003 | 92 | 0.030 |
Why?
|
| Methylmalonic Acid | 1 | 2012 | 14 | 0.030 |
Why?
|
| Estrogens | 1 | 2015 | 506 | 0.030 |
Why?
|
| Ehlers-Danlos Syndrome | 1 | 2013 | 40 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2016 | 558 | 0.030 |
Why?
|
| Mice, Inbred Strains | 1 | 2003 | 317 | 0.030 |
Why?
|
| Vasoplegia | 1 | 2012 | 10 | 0.030 |
Why?
|
| Gene Library | 1 | 2013 | 218 | 0.030 |
Why?
|
| Length of Stay | 1 | 2017 | 1250 | 0.020 |
Why?
|
| Critical Care | 1 | 2017 | 643 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2017 | 2438 | 0.020 |
Why?
|
| Apoptosis | 1 | 1998 | 1788 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2011 | 37 | 0.020 |
Why?
|
| DNA | 3 | 2003 | 1607 | 0.020 |
Why?
|
| Medical Informatics | 1 | 2013 | 107 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2018 | 2826 | 0.020 |
Why?
|
| Glucose | 1 | 2016 | 876 | 0.020 |
Why?
|
| Infant Formula | 1 | 2012 | 98 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2015 | 1564 | 0.020 |
Why?
|
| Hospitalization | 1 | 2019 | 1719 | 0.020 |
Why?
|
| Gene Order | 1 | 2011 | 78 | 0.020 |
Why?
|
| Segmental Duplications, Genomic | 1 | 2011 | 81 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 598 | 0.020 |
Why?
|
| Insulin | 1 | 2016 | 1190 | 0.020 |
Why?
|
| Arginine | 1 | 2003 | 303 | 0.020 |
Why?
|
| Patient Safety | 1 | 2015 | 389 | 0.020 |
Why?
|
| Chromosome Breakage | 1 | 2011 | 168 | 0.020 |
Why?
|
| Logistic Models | 1 | 2015 | 1756 | 0.020 |
Why?
|
| Ethics, Professional | 1 | 2010 | 18 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2012 | 353 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2017 | 1923 | 0.020 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2009 | 30 | 0.020 |
Why?
|
| Sex Chromosome Disorders | 1 | 2009 | 8 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2003 | 438 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2013 | 968 | 0.020 |
Why?
|
| Respiratory Insufficiency | 1 | 2012 | 234 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2020 | 5906 | 0.020 |
Why?
|
| Biocatalysis | 1 | 2009 | 33 | 0.020 |
Why?
|
| Overweight | 1 | 2012 | 339 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2012 | 492 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2010 | 192 | 0.020 |
Why?
|
| Periventricular Nodular Heterotopia | 1 | 2008 | 7 | 0.020 |
Why?
|
| Central Nervous System Cysts | 1 | 2008 | 11 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2011 | 664 | 0.020 |
Why?
|
| Neuroimaging | 1 | 2011 | 325 | 0.020 |
Why?
|
| Gender Identity | 1 | 2009 | 68 | 0.020 |
Why?
|
| Skin Pigmentation | 1 | 2008 | 27 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 2792 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2008 | 79 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2015 | 1674 | 0.020 |
Why?
|
| Granzymes | 2 | 1998 | 39 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2009 | 751 | 0.020 |
Why?
|
| Sex | 1 | 2007 | 8 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2008 | 352 | 0.020 |
Why?
|
| Polysomnography | 1 | 2008 | 133 | 0.020 |
Why?
|
| Polymorphism, Genetic | 2 | 2003 | 804 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2009 | 222 | 0.020 |
Why?
|
| Hernia, Inguinal | 1 | 2007 | 40 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 2 | 1998 | 1077 | 0.020 |
Why?
|
| Cytotoxicity, Immunologic | 2 | 1998 | 261 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2011 | 935 | 0.020 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2007 | 164 | 0.020 |
Why?
|
| Fragile X Mental Retardation Protein | 1 | 2007 | 125 | 0.020 |
Why?
|
| Femoral Artery | 1 | 2007 | 168 | 0.020 |
Why?
|
| Leg | 1 | 2007 | 152 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2009 | 1069 | 0.020 |
Why?
|
| Time Factors | 1 | 2015 | 5995 | 0.020 |
Why?
|
| Cerebellum | 1 | 2008 | 410 | 0.020 |
Why?
|
| Testis | 1 | 2007 | 407 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 1680 | 0.010 |
Why?
|
| Sulfites | 1 | 2003 | 30 | 0.010 |
Why?
|
| Nondisjunction, Genetic | 1 | 2003 | 19 | 0.010 |
Why?
|
| Electroencephalography | 1 | 2008 | 842 | 0.010 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2003 | 63 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2007 | 1460 | 0.010 |
Why?
|
| Steryl-Sulfatase | 1 | 2002 | 21 | 0.010 |
Why?
|
| Spectral Karyotyping | 1 | 2002 | 8 | 0.010 |
Why?
|
| Isochromosomes | 1 | 2002 | 18 | 0.010 |
Why?
|
| Polyhydramnios | 1 | 2002 | 51 | 0.010 |
Why?
|
| Amniocentesis | 1 | 2002 | 77 | 0.010 |
Why?
|
| Respiratory Tract Diseases | 1 | 2002 | 77 | 0.010 |
Why?
|
| alpha-Fetoproteins | 1 | 2002 | 136 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 2001 | 217 | 0.010 |
Why?
|
| Neoplasms | 1 | 2015 | 2748 | 0.010 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2002 | 152 | 0.010 |
Why?
|
| Translocation, Genetic | 1 | 2002 | 344 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 2003 | 314 | 0.010 |
Why?
|
| Caspase Inhibitors | 1 | 1998 | 29 | 0.010 |
Why?
|
| Pore Forming Cytotoxic Proteins | 1 | 1998 | 10 | 0.010 |
Why?
|
| fas Receptor | 1 | 1998 | 43 | 0.010 |
Why?
|
| Perforin | 1 | 1998 | 18 | 0.010 |
Why?
|
| Cholic Acids | 1 | 1998 | 16 | 0.010 |
Why?
|
| Nuclear Envelope | 1 | 1998 | 17 | 0.010 |
Why?
|
| Cell Nucleolus | 1 | 1998 | 56 | 0.010 |
Why?
|
| Liver Neoplasms, Experimental | 1 | 1998 | 66 | 0.010 |
Why?
|
| Cytosol | 1 | 1998 | 160 | 0.010 |
Why?
|
| Biological Transport | 1 | 1998 | 348 | 0.010 |
Why?
|
| Monosomy | 1 | 1997 | 24 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 1998 | 288 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 1998 | 330 | 0.010 |
Why?
|
| Biopsy | 1 | 2001 | 1242 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 1998 | 259 | 0.010 |
Why?
|
| Transfection | 1 | 1998 | 1076 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 1998 | 814 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 1998 | 416 | 0.010 |
Why?
|
| Bone Marrow | 1 | 1996 | 317 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 1996 | 1698 | 0.010 |
Why?
|